Navigation Links
Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
Date:9/30/2008

SAN DIEGO, Sept. 30 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will present at the JMP Securities 3rd Annual Healthcare Focus Conference on Tuesday, October 7, 2008 at 3:00 p.m. EDT (12:00 p.m. PDT). The conference is being held at Le Parker Meridien in New York City.

Steve Worland, Ph.D., President and Chief Executive Officer of Anadys, will present an overview of Anadys and its three clinical programs: ANA598 and ANA773 in hepatitis C and ANA773 in cancer.

The presentation will be simultaneously webcast and can be accessed on the Investor Relations page of the Company's website at http://www.anadyspharma.com. Listeners are encouraged to visit the website approximately five minutes prior to the corporate presentation to download or install any necessary software. A replay of the presentation will be available approximately one hour after the live webcast concludes and will be available through October 21, 2008.

About Anadys

Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of chronic hepatitis C, the Company is developing two potentially complementary agents, ANA598, a non-nucleoside polymerase inhibitor and ANA773, an oral TLR7 agonist prodrug. The Company is also developing ANA773 for the treatment of cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Anadys' strategy, development prog
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
2. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
3. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
4. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
5. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
6. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
7. Potentia Pharmaceuticals Announces Positive Safety Data and Study Expansion in Phase I Trial for Lead Drug Candidate POT-4
8. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
9. Lotus Pharmaceuticals, Inc.s New Drug Laevo-Bambutero Begins Evaluation for Clinical Trials
10. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial
11. QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2009)...CHICAGO, Nov. 30 Elastography is a... to breast ultrasound, helps distinguish cancerous...an ongoing study presented today at the annual mee...(RSNA). ,, When mammography yields suspicious f... additional information. However, ultrasound has t...
(Date:11/29/2009)..., IOWA CITY, Iowa and ST. LOUIS, Nov. 29 /PRNewsw...uantitative imaging software for the advanced anal...nologies, a leader in minimally invasive delivery ...e companies have signed a definitive agreement cov...obronchial lung navigation and biopsy system. ,...
(Date:11/29/2009)...CHICAGO, Nov. 29 Researchers using...tudy brain activation have found that men and wome...muli, according to a study presented today at the ...h America (RSNA). ,, "Men may direct more atten...end to process them in terms of implications for r...
Breaking Medicine Technology:Elastography Reduces Unnecessary Breast Biopsies 2Elastography Reduces Unnecessary Breast Biopsies 3VIDA Diagnostics and Veran Medical Sign Definitive Agreement for Joint Development of Endobronchial Navigation System 2VIDA Diagnostics and Veran Medical Sign Definitive Agreement for Joint Development of Endobronchial Navigation System 3VIDA Diagnostics and Veran Medical Sign Definitive Agreement for Joint Development of Endobronchial Navigation System 4New Study Finds Men and Women May Respond Differently to Danger 2New Study Finds Men and Women May Respond Differently to Danger 3BioMarin to Present at the Morgan Stanley Healthcare Conference 13892 1BioMarin to Present at the Morgan Stanley Healthcare Conference 13892 2Will the FDA Ban Hydroquinone in Pigment Control Products 3F 56380 1Will the FDA Ban Hydroquinone in Pigment Control Products 3F 56380 2Will the FDA Ban Hydroquinone in Pigment Control Products 3F 56380 3OneBeacon Professional Partners and Medversant Offer New Electronic Credentialing Solution to Managed Care Organizations 56375 1OneBeacon Professional Partners and Medversant Offer New Electronic Credentialing Solution to Managed Care Organizations 56375 2OneBeacon Professional Partners and Medversant Offer New Electronic Credentialing Solution to Managed Care Organizations 56375 3OneBeacon Professional Partners and Medversant Offer New Electronic Credentialing Solution to Managed Care Organizations 56375 4OneBeacon Professional Partners and Medversant Offer New Electronic Credentialing Solution to Managed Care Organizations 56375 5
...Form of a GLP1-analog Aimed at Improving Glyc...SALEM, Israel, September 16 Oramed,Pharmaceutical... delivery,systems, announced today that it has lau...log., ORMD 0901 belongs to the Incretin family of...eduction in blood glucose levels and inhibiting,gl...
... France, Sept. 16, DSM and LibraGen, a bacterial d...nnounced today that they have signed an agreement ...on of chiral amines. Under,the terms of the partne...scovery and development to identify new enzymes fo...ns into optically pure R- and S-amines, a,compound...
Other Medicine Technology:Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug Delivery Platform 2DSM and LibraGen Sign Agreement to Co-Develop Transaminases for Production of Chiral Amines 2DSM and LibraGen Sign Agreement to Co-Develop Transaminases for Production of Chiral Amines 3
(Date:11/30/2009)...treating a tumor without disturbing normal tissue ...therapies can be invasive and harsh. , Researche...a way they might deliver the right therapy directl...rs, which specifically bind to living tumor tissue...rodent with liver cancer until they found the best...
(Date:11/30/2009)...owMyPC has released an online service that lets us...e. This is the first hosted service in the world t...rogram. Result, blazing fast performance even over...nta Clara, CA (PRWEB) November 30, 2009 -- ShowMyP...ess Service that uses the familiar Microsoft Remot...
(Date:11/30/2009)... best serve our patients, their caregivers, and ou...itute of Women,s Health of North America in Florid... service is available to all individuals (male and...te to locate a convenient LOCATION near you or c...cus) November 30, 2009 -- According to the most re...
(Date:11/30/2009)...wyers from The Healy Law Firm secure the highest p... of man rendered an incomplete quadriplegic. , ...vember 30, 2009 -- A Cook County jury has entered ...rant carpenter, 22 years old at the time, who dove...te quadriplegic. The verdict, which was reduced t...
(Date:11/30/2009)...oking is on the rise in the developing world but f...mitment to stop smoking cigarette, but the recent ...actually help people quit smoking cigarette. htt...gnated to help heavy smokers cut down on their cig... Los Angeles, CA (PRWEB) November 30, 200...
Breaking Medicine News(10 mins):Health News:First live targeting of tumors with RNA-based technology 2Health News:First live targeting of tumors with RNA-based technology 3Health News:ShowMyPC Provides First Online Service in the World to Access Personal Computers from Anywhere Using Microsoft Remote Desktop 2Health News:2009 H1N1 Influenza Vaccination Being Offered at Various Affiliated Campuses of the Institute of Women's Health of North America in Florida 2Health News:2009 H1N1 Influenza Vaccination Being Offered at Various Affiliated Campuses of the Institute of Women's Health of North America in Florida 3Health News:Cook County Jury Awards a Gross Verdict of $8.1 Million to Victim of Swimming Pool Accident 2Health News:Cook County Jury Awards a Gross Verdict of $8.1 Million to Victim of Swimming Pool Accident 3Health News:Stop Smoking Cigarette with Electronic Cigarette (E-Cig), Today You Can Quit Smoking Too 2
... survival rate of breast cancer patients by 63 per...rd regimes available . The clinical trial strength...mestane, as a first option.// A study showed that ...ears of tamoxifen treatment. According to the ...
... 6 million Americans are allergic to fish and shel...r ‘convincing allergy’ // to seafood is reported b...about 6.5 million Americans.” In a recent stud... households to determine the prevalence of self-re...
...tific evidence that mental stress alone can trigge...bances // in normal heart rhythm. Researchers stud...were under mental and physical stress. They includ...cent incident that made them angry and also by hav...
...n extreme pain that can last for months. Now a sim..., up to 14,000 people // over age 60 develop shing...hicken pox virus. A new study shows tai chi -- ...n shown to help illnesses such as Parkinson's dise...
...y researchers shows young breast cancer survivors ...patients. // As patients may not be getting the ap...math of the disease. Researchers sampled nearly... that 65 percent of the respondents were still und...
...e of antidepressants in children is increasing at ...gs are not safe // and may actually increase a chi...nalyzed drug prescriptions written for more than 5... selective serotonin reuptake inhibitor ( SSRI ) s...
Other Medicine News:
BET/1P-ERB - Tubular Base - Model 1P63
BET/1P-ERB - Tubular Base - Model 1P61-ERB
BET/1P-ERB - Tubular Base - Model 1P42-ERB
BET/1P-ERB - Tubular Base - Model 1P42-R-ERB
Medicine Products: